We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
China's Aida Pharmaceuticals has expanded its drug development pipeline with the acquisition of three new drugs -- one with potential to treat immune disorders and two anticancer drugs.
Schering AG workers are worried that the higher price paid by Bayer AG for the company will result in job cuts, head of the works council Norbert Deutschmann told Die Welt.
Cambrex Corporation and Cytori Therapeutics have entered into a strategic marketing agreement to provide adipose-derived stem cell products globally for use in basic and translational bioresearch.
Mylan Laboratories Inc. announced today that the regular quarterly cash dividend of $.06 per share will be payable on July 14, 2006, to shareholders of record at the close of business on June 30, 2006.
The FDA has placed a rare clinical hold on a trial sponsored by Corautus Genetics after the company reported three severe adverse events in a 10-day period.
The FDA has given clearance for a Phase I/II clinical trial of Hollis-Eden's investigational compound Neumune, which combats healthcare-associated (nosocomial) infections.
The FDA is growing increasingly concerned about its own practice of requiring companies to provide risk management plans (RMPs) as a condition of drug approvals, a high-ranking agency official said.